Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of Stage II disease

D. H. Berdeaux, F. L. Meyskens, B. Parks, T. Tong, Lois J Loescher, T. E. Moon

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The survival history of 259 patients with Stage I cutaneous malignant melanoma who were at risk for developing regional nodal metastases (Stage II) were studied. Eighty-seven of 377 Stage I patients (23%) developed regional nodal metastases (Stage II(B)) with 40% 5-year survival. Fifty patients had regional nodal metastases at presentation, with or without a known primary (Stages II(A) or II(C), respectively), with a 42% 5-year survival. A step-down multivariate analysis using the Cox regression model revealed four risk factors as being highly significant for predicting a more favorable survival outcome: (1) thinner Breslow thickness (P = 0.0001), (2) pathologic Stage I disease (P = 0.004), (3) no clinical ulceration (P = 0.0004), and (4) being a woman younger than 50 years of age (P = 0.029). These results are discussed in reference to other series.

Original languageEnglish (US)
Pages (from-to)1430-1436
Number of pages7
JournalCancer
Volume63
Issue number7
StatePublished - 1989

Fingerprint

Natural History
Survival
Neoplasm Metastasis
Proportional Hazards Models
Multivariate Analysis
Cutaneous Malignant Melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Berdeaux, D. H., Meyskens, F. L., Parks, B., Tong, T., Loescher, L. J., & Moon, T. E. (1989). Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of Stage II disease. Cancer, 63(7), 1430-1436.

Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of Stage II disease. / Berdeaux, D. H.; Meyskens, F. L.; Parks, B.; Tong, T.; Loescher, Lois J; Moon, T. E.

In: Cancer, Vol. 63, No. 7, 1989, p. 1430-1436.

Research output: Contribution to journalArticle

Berdeaux, DH, Meyskens, FL, Parks, B, Tong, T, Loescher, LJ & Moon, TE 1989, 'Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of Stage II disease', Cancer, vol. 63, no. 7, pp. 1430-1436.
Berdeaux, D. H. ; Meyskens, F. L. ; Parks, B. ; Tong, T. ; Loescher, Lois J ; Moon, T. E. / Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of Stage II disease. In: Cancer. 1989 ; Vol. 63, No. 7. pp. 1430-1436.
@article{9a0cbef9b6984150b05060e8b2d39059,
title = "Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of Stage II disease",
abstract = "The survival history of 259 patients with Stage I cutaneous malignant melanoma who were at risk for developing regional nodal metastases (Stage II) were studied. Eighty-seven of 377 Stage I patients (23{\%}) developed regional nodal metastases (Stage II(B)) with 40{\%} 5-year survival. Fifty patients had regional nodal metastases at presentation, with or without a known primary (Stages II(A) or II(C), respectively), with a 42{\%} 5-year survival. A step-down multivariate analysis using the Cox regression model revealed four risk factors as being highly significant for predicting a more favorable survival outcome: (1) thinner Breslow thickness (P = 0.0001), (2) pathologic Stage I disease (P = 0.004), (3) no clinical ulceration (P = 0.0004), and (4) being a woman younger than 50 years of age (P = 0.029). These results are discussed in reference to other series.",
author = "Berdeaux, {D. H.} and Meyskens, {F. L.} and B. Parks and T. Tong and Loescher, {Lois J} and Moon, {T. E.}",
year = "1989",
language = "English (US)",
volume = "63",
pages = "1430--1436",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Cutaneous malignant melanoma. II. The natural history and prognostic factors influencing the development of Stage II disease

AU - Berdeaux, D. H.

AU - Meyskens, F. L.

AU - Parks, B.

AU - Tong, T.

AU - Loescher, Lois J

AU - Moon, T. E.

PY - 1989

Y1 - 1989

N2 - The survival history of 259 patients with Stage I cutaneous malignant melanoma who were at risk for developing regional nodal metastases (Stage II) were studied. Eighty-seven of 377 Stage I patients (23%) developed regional nodal metastases (Stage II(B)) with 40% 5-year survival. Fifty patients had regional nodal metastases at presentation, with or without a known primary (Stages II(A) or II(C), respectively), with a 42% 5-year survival. A step-down multivariate analysis using the Cox regression model revealed four risk factors as being highly significant for predicting a more favorable survival outcome: (1) thinner Breslow thickness (P = 0.0001), (2) pathologic Stage I disease (P = 0.004), (3) no clinical ulceration (P = 0.0004), and (4) being a woman younger than 50 years of age (P = 0.029). These results are discussed in reference to other series.

AB - The survival history of 259 patients with Stage I cutaneous malignant melanoma who were at risk for developing regional nodal metastases (Stage II) were studied. Eighty-seven of 377 Stage I patients (23%) developed regional nodal metastases (Stage II(B)) with 40% 5-year survival. Fifty patients had regional nodal metastases at presentation, with or without a known primary (Stages II(A) or II(C), respectively), with a 42% 5-year survival. A step-down multivariate analysis using the Cox regression model revealed four risk factors as being highly significant for predicting a more favorable survival outcome: (1) thinner Breslow thickness (P = 0.0001), (2) pathologic Stage I disease (P = 0.004), (3) no clinical ulceration (P = 0.0004), and (4) being a woman younger than 50 years of age (P = 0.029). These results are discussed in reference to other series.

UR - http://www.scopus.com/inward/record.url?scp=0024555998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024555998&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 1430

EP - 1436

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -